Early development of anti-natalizumab antibodies in MS patients
- 14 June 2013
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 260 (9), 2343-2347
- https://doi.org/10.1007/s00415-013-6991-2
Abstract
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the efficacy of the treatment and an increase of adverse events. A total of 134 multiple sclerosis patients were included in the trial. Anti-natalizumab antibodies were monthly detected by ELISA up to the first year of treatment and subsequently, a determination was made at 18 months. 15.7% of the patients were positive, being 7.5% transiently positive and 8.2% persistently positive. The first appearance of anti-natalizumab antibodies occurred after the first month of treatment onset in 72% of positive patients; 18% did so after the second month, and 9.7% after the third month. Antibodies were never detected for the first time after the fourth infusion. The development of anti-natalizumab antibodies occurs very early after treatment onset. This observation should be considered when standardizing the follow up of patients treated with this drug in order to minimize the risks and optimize the treatment.This publication has 8 references indexed in Scilit:
- Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumabMultiple Sclerosis Journal, 2011
- Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumabNeurology, 2011
- Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 monthsMultiple Sclerosis Journal, 2010
- The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational studyMultiple Sclerosis Journal, 2010
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory DiseasesCNS Drug Reviews, 2007
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006